PE20240227A1 - Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos - Google Patents
Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninosInfo
- Publication number
- PE20240227A1 PE20240227A1 PE2023001843A PE2023001843A PE20240227A1 PE 20240227 A1 PE20240227 A1 PE 20240227A1 PE 2023001843 A PE2023001843 A PE 2023001843A PE 2023001843 A PE2023001843 A PE 2023001843A PE 20240227 A1 PE20240227 A1 PE 20240227A1
- Authority
- PE
- Peru
- Prior art keywords
- children
- myopia
- progression
- inhibitor
- eye drops
- Prior art date
Links
- 230000004515 progressive myopia Effects 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000003889 eye drop Substances 0.000 title abstract 2
- 229940012356 eye drops Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 abstract 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 abstract 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
Abstract
La presente invencion se refiere a gotas para los ojos para inhibir la progresion de la miopia en ninos, que contiene como ingrediente activo un inhibidor de la via de PERK (quinasa del reticulo endoplasmatico similar a PKR) y/o de la via de ATF6 (factor de transcripcion activador 6), el cual es al menos uno seleccionado del grupo que consiste en acido fenilbutirico y sales farmacologicamente aceptables del mismo. Tambien se refiere a un metodo de cribado del inhibidor de la progresion de la miopia en ninos y su uso
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020205489 | 2020-12-11 | ||
PCT/JP2021/032067 WO2022123836A1 (ja) | 2020-12-11 | 2021-09-01 | 小児の近視進行抑制用点眼剤及び小児の近視進行抑制剤のスクリーニング方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240227A1 true PE20240227A1 (es) | 2024-02-16 |
Family
ID=81973514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001843A PE20240227A1 (es) | 2020-12-11 | 2021-09-01 | Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240041806A1 (es) |
EP (1) | EP4257147A1 (es) |
JP (1) | JPWO2022123836A1 (es) |
KR (1) | KR20230135054A (es) |
CN (1) | CN116761595A (es) |
AU (1) | AU2021396680A1 (es) |
CA (1) | CA3204753A1 (es) |
CL (1) | CL2023001634A1 (es) |
IL (1) | IL303499A (es) |
MA (1) | MA61683A1 (es) |
MX (1) | MX2023006723A (es) |
PE (1) | PE20240227A1 (es) |
TW (1) | TW202237075A (es) |
WO (1) | WO2022123836A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115645536A (zh) * | 2017-03-06 | 2023-01-31 | 坪田实验室股份有限公司 | 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 |
CN107898793B (zh) * | 2017-12-01 | 2019-12-24 | 温州医科大学 | 一种抑制近视的方法及制备药物的应用 |
-
2021
- 2021-09-01 MA MA61683A patent/MA61683A1/fr unknown
- 2021-09-01 IL IL303499A patent/IL303499A/en unknown
- 2021-09-01 PE PE2023001843A patent/PE20240227A1/es unknown
- 2021-09-01 WO PCT/JP2021/032067 patent/WO2022123836A1/ja active Application Filing
- 2021-09-01 MX MX2023006723A patent/MX2023006723A/es unknown
- 2021-09-01 KR KR1020237022414A patent/KR20230135054A/ko unknown
- 2021-09-01 TW TW110132525A patent/TW202237075A/zh unknown
- 2021-09-01 CN CN202180082953.5A patent/CN116761595A/zh active Pending
- 2021-09-01 CA CA3204753A patent/CA3204753A1/en active Pending
- 2021-09-01 JP JP2022568049A patent/JPWO2022123836A1/ja active Pending
- 2021-09-01 US US18/266,102 patent/US20240041806A1/en active Pending
- 2021-09-01 AU AU2021396680A patent/AU2021396680A1/en active Pending
- 2021-09-01 EP EP21902941.0A patent/EP4257147A1/en active Pending
-
2023
- 2023-06-06 CL CL2023001634A patent/CL2023001634A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4257147A1 (en) | 2023-10-11 |
MX2023006723A (es) | 2023-09-21 |
KR20230135054A (ko) | 2023-09-22 |
CA3204753A1 (en) | 2022-06-16 |
TW202237075A (zh) | 2022-10-01 |
IL303499A (en) | 2023-08-01 |
US20240041806A1 (en) | 2024-02-08 |
JPWO2022123836A1 (es) | 2022-06-16 |
MA61683A1 (fr) | 2023-08-31 |
CN116761595A (zh) | 2023-09-15 |
WO2022123836A1 (ja) | 2022-06-16 |
AU2021396680A9 (en) | 2024-05-30 |
AU2021396680A1 (en) | 2023-07-06 |
CL2023001634A1 (es) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
NI201500120A (es) | Compuestos de biaril - amida como inhibidores de cinasa | |
CL2017002650A1 (es) | Compuestos novedosos | |
ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
CL2021002772A1 (es) | Moduladores de la vía de respuesta integrada al estrés | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
AR091677A1 (es) | INHIBIDORES DE PI3K d SELECTIVOS | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
PE20211794A1 (es) | Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico | |
UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
CO6612202A2 (es) | Inhibidores heterparílicos bicíclicos de pde4 | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |